General Information of Drug (ID: DMMYUWT)

Drug Name
GSK-923295 Drug Info
Synonyms
1088965-37-0; GSK-923295; GSK923295; 3-Chloro-N-((S)-1-(2-(dimethylamino)acetamido)-3-(4-(8-((S)-1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl)phenyl)propan-2-yl)-4-isopropoxybenzamide; 3-Chloro-N-((S)-1-(2-(dimethylamino)acetamido)-3-(4-(8-((S)-1-hydroxyethyl)-imidazo[1,2-a]pyridin-2-yl)phenyl)propan-2-yl)-4-isopropoxybenzamide; GSK 923295; MLS006011170; SCHEMBL1492164; UNII-072702W9QD; CTK8C0600; DTXSID50677145; GSK-295; AOB5937; EX-A633; MolPort-023-332-816; GSK-923295A; BCP09858; ANW-64945; s7090; ZINC68151184; AKOS016005270
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
46898058
ChEBI ID
CHEMBL4303470
CAS Number
CAS 1088965-37-0
TTD Drug ID
D00XEU

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome 2.29 0.00e+0 113/158 (71.52%) MRPS16;RPL36;RPL14;...
Intestinal immune network for IgA production 2.19 0.00e+0 38/48 (79.17%) CD40;HLA-DQA1;HLA-DRB1;...
Proteasome 2.16 0.00e+0 44/46 (95.65%) IFNG;PSMB2;PSMD4;...
Spliceosome 2.06 8.75e-3 101/150 (67.33%) SNRPE;SNRPD1;SNRPF;...
Natural killer cell mediated cytotoxicity 2.05 7.00e-3 99/131 (75.57%) KLRK1;LCK;IFNG;...
T cell receptor signaling pathway 2.00 5.83e-3 93/104 (89.42%) LCK;NFATC3;PRKCQ;...
PD-L1 expression and PD-1 checkpoint pathway in cancer 1.95 6.67e-3 79/89 (88.76%) TLR4;LCK;NFATC3;...
Prion disease 1.90 1.17e-2 209/273 (76.56%) ATP5MC2;ATP5MC1;PSMB2;...
Asthma 1.90 1.04e-2 25/31 (80.65%) CD40;HLA-DQA1;HLA-DRB1;...
Systemic lupus erythematosus 1.86 1.40e-2 45/135 (33.33%) CD40;HLA-DQA1;ACTN1;...
Autoimmune thyroid disease 1.85 1.27e-2 46/53 (86.79%) CD40;HLA-DQA1;GZMB;...
Huntington disease 1.85 1.17e-2 233/306 (76.14%) ATP5MC2;ATP5MC1;PSMB2;...
Th1 and Th2 cell differentiation 1.85 1.08e-2 80/92 (86.96%) HLA-DQA1;LCK;NFATC3;...
Amyotrophic lateral sclerosis 1.83 1.25e-2 267/364 (73.35%) NEFH;ATP5MC2;ATP5MC1;...
Primary immunodeficiency 1.82 1.17e-2 33/38 (86.84%) CD40;LCK;CD8A;...
Type I diabetes mellitus 1.82 1.09e-2 38/43 (88.37%) HLA-DQA1;PTPRN2;IFNG;...
Neutrophil extracellular trap formation 1.80 1.30e-2 101/189 (53.44%) TLR4;FPR1;SLC25A6;...
Parkinson disease 1.77 1.30e-2 176/249 (70.68%) SNCA;ATP5MC2;ATP5MC1;...
Pathways of neurodegeneration 1.72 1.90e-2 354/475 (74.53%) DKK1;SNCA;NEFH;...
Th17 cell differentiation 1.71 1.98e-2 95/107 (88.79%) HLA-DQA1;HSP90AA1;LCK;...
Allograft rejection 1.70 1.94e-2 32/38 (84.21%) CD40;HLA-DQA1;IFNG;...
Ribosome biogenesis in eukaryotes 1.68 2.49e-2 52/108 (48.15%) NOP56;POP5;NMD3;...
Graft-versus-host disease 1.67 2.49e-2 32/42 (76.19%) HLA-DQA1;IFNG;GZMB;...
Spinocerebellar ataxia 1.67 2.38e-2 128/143 (89.51%) PSMB2;PSMD4;NOP56;...
Viral protein interaction with cytokine and cytokine re... 1.65 2.75e-2 84/100 (84%) CXCL1;CXCL8;CXCL3;...
Alzheimer disease 1.65 2.74e-2 279/369 (75.61%) DKK1;SNCA;FRAT2;...
VEGF signaling pathway 1.64 2.89e-2 50/59 (84.75%) PPP3CA;SPHK1;PRKCB;...
Mineral absorption 1.63 3.04e-2 48/60 (80%) MT2A;MT1H;MT1G;...
Lipid and atherosclerosis 1.61 3.13e-2 190/215 (88.37%) TLR4;CD40;CXCL1;...
Inflammatory bowel disease 1.61 3.11e-2 58/65 (89.23%) TLR4;HLA-DQA1;IFNG;...
ECM-receptor interaction -2.03 2.12e-2 80/88 (90.91%) LAMB3;LAMB1;FN1;...
Steroid biosynthesis -2.25 0.00e+0 19/20 (95%) FDFT1;CYP51A1;HSD17B7;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 2.22uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 2.22uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 2.22uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 2.22uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H